Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Significant clinical worsening after natalizumab withdrawal: Predictive factors.
Phosphodiesterase 5 inhibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions.
Multiple sclerosis.
The Lateral Membrane Organization and Dynamics of Myelin Proteins PLP and MBP Are Dictated by Distinct Galactolipids and the Extracellular Matrix.
Progressive Disorganization of Paranodal Junctions and Compact Myelin Due to Loss of DCC Expression by Oligodendrocytes.
Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis.
Evaluation of visual structural and functional factors that predict the development of multiple sclerosis in clinically isolated syndrome patients.
The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration.
From genes to characteristics of multiple sclerosis.
Immunomodulatory synergy by combining atorvastatin and rapamycin in the treatment of experimental autoimmune encephalomyelitis (EAE).
Myelin reactive T cells after T cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations.
Determining the Presence of Reliable Change over Time in Multiple Sclerosis: Evidence from the PASAT, Adjusting-PSAT, and Stroop Test.
Bee Venom Acupuncture Alleviates Experimental Autoimmune Encephalomyelitis by Upregulating Regulatory T Cells and Suppressing Th1 and Th17 Responses.
The high cost of spasticity in multiple sclerosis to individuals and society.
miR-17-92 cluster targets Phosphatase and Tensin Homology and Ikaros Family Zinc Finger 4 to promote TH17-mediated inflammation.
CNS demyelinating disorder with mixed features of neuromyelitis optica and multiple sclerosis in HIV-1 infection. Case report and literature review.
Features of sleep disturbances in multiple sclerosis patients.
Aquatic training in MS: neurotherapeutic impact upon quality of life.
Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.
Determinants of ligand binding and catalytic activity in the myelin enzyme 2',3'-cyclic nucleotide 3'-phosphodiesterase.
Dibutyryl Cyclic AMP Inhibits the Progression of Experimental Autoimmune Encephalomyelitis and Potentiates Recruitment of Endogenous Neural Stem Cells.
Vowel Acoustics in Parkinson's disease and Multiple Sclerosis: Comparison of Clear, Loud and Slow Speaking Conditions.
Patient-related factors may affect the outcome of neuropsychological rehabilitation in multiple sclerosis.
Effect of short-term interferon-β treatment on cytokines in multiple sclerosis: Significant modulation of IL-17 and IL-23.
Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis.
Pages
« first
‹ previous
…
309
310
311
312
313
314
315
316
317
…
next ›
last »